PLAQSIRISNCT06440317
Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved at least 5 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Start date changed from estimate of Apr 2026 to Oct 22, 2026
- Eligibility criteria expanded, about 4 words
- Primary completion pushed from Apr 2027 to Oct 2027
- Study completion pushed from May 2027 to Nov 2027
- Notable Primary completion date: Jan 2026 to Apr 2027
- Start date: Jan 2025 to Apr 2026
- Study completion date: Feb 2026 to May 2027
- Notable Start date: Jul 2024 to Jan 2025
- Primary completion date: Jul 2025 to Jan 2026
- Study completion date: Aug 2025 to Feb 2026
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Primary completion date: Jun 2025 to Jul 2025
- Study completion date: Jul 2025 to Aug 2025
- Start date: Jun 2024 to Jul 2024
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Immunothrombosis : Concentration of platelet activation markers
Timeframe: 12 months after inclusion day
Secondary (2)
NETosis : Concentration of Neutrophil Extracellular Traps
Monocyte activation : Concentration of monocyte (CD14+)
Arms and interventions
Hemofiltration membranes (the oXiris® membrane and the HF1400 ® membrane)
Eligible patients for this study will undergo renal replacement therapy using two hemofiltration membranes commonly used in intensive care units.
Devices: Hemofiltration membranes (the oXiris membrane® and the HF1400® membrane)
Sites
1 site in 1 country
- Hopital Haut-LévêquePessac, France